Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
Authors
Keywords
-
Journal
Cancer Communications
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-03-10
DOI
10.1002/cac2.12153
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy
- (2020) Annikka Weissferdt et al. Clinical Lung Cancer
- The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
- (2020) Xiuli Tao et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Sequence of biologic therapies and surgery affects survival in non–small cell lung cancer
- (2020) Edison Xu et al. JOURNAL OF SURGICAL ONCOLOGY
- Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
- (2020) Catherine A Shu et al. LANCET ONCOLOGY
- Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
- (2020) Omid Kooshkaki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches
- (2020) Dipesh Uprety et al. Journal of Thoracic Oncology
- Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I–IIIA non-small cell lung cancer: a propensity-matched analysis
- (2020) Junjie Xi et al. Journal of Thoracic Disease
- 1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
- (2020) M. Wislez et al. ANNALS OF ONCOLOGY
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
- (2020) Chris Dickhoff et al. BMC CANCER
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis
- (2020) Xiao-hui Jia et al. LUNG CANCER
- Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
- (2020) Arafat Tfayli et al. Cancer Medicine
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
- (2020) Joshua E Reuss et al. Journal for ImmunoTherapy of Cancer
- Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
- (2020) Muyun Peng et al. Frontiers in Oncology
- The mortality of lung cancer attributable to smoking among adults in China and the United States during 1990–2017
- (2020) Xiaoxue Liu et al. Cancer Communications
- Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- (2019) K M Heinhuis et al. ANNALS OF ONCOLOGY
- The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
- (2019) Åsa Kristina Öjlert et al. Molecular Oncology
- The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
- (2019) M. G. Dal Bello et al. Journal of Translational Medicine
- Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system?†
- (2019) Hüseyin Melek et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
- (2019) Florian Eichhorn et al. BMC CANCER
- Gut microbiome and cancer immunotherapy
- (2019) Weina Li et al. CANCER LETTERS
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
- (2019) Rodabe N Amaria et al. LANCET ONCOLOGY
- Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
- (2019) Claire Lhuillier et al. Genome Medicine
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
- (2019) Alessandro Leonetti et al. DRUG RESISTANCE UPDATES
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
- (2019) Bradon R. McDonald et al. Science Translational Medicine
- Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
- (2019) Jiajia Zhang et al. CLINICAL CANCER RESEARCH
- P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)
- (2019) N. Altorki et al. Journal of Thoracic Oncology
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
- (2019) Spencer C. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape
- (2019) Wei Xia et al. MEDICAL SCIENCE MONITOR
- Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer
- (2019) Hideharu Kimura et al. Cancer Communications
- Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
- (2019) Elizabeth Ahern et al. Trials
- Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
- (2019) Martin Reck et al. Expert Review of Respiratory Medicine
- Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients
- (2018) Seth B. Krantz et al. ANNALS OF THORACIC SURGERY
- Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors
- (2018) Matthew J. Bott et al. ANNALS OF THORACIC SURGERY
- Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer
- (2018) Chi-Fu Jeffrey Yang et al. ANNALS OF THORACIC SURGERY
- Pseudoprogression and hyperprogression after checkpoint blockade
- (2018) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report
- (2018) Yuki Owada-Ozaki et al. Journal of Thoracic Oncology
- Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection
- (2018) Christopher Abbosh et al. Nature Reviews Clinical Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
- (2018) Laurence Zitvogel et al. SCIENCE
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
- (2018) Marie-Claude Bourgeois-Daigneault et al. Science Translational Medicine
- PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma
- (2018) Bojan Zaric et al. Clinical Lung Cancer
- Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
- (2018) Yang Liu et al. Journal of Hematology & Oncology
- Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma
- (2018) Hui Yu et al. Journal of Thoracic Oncology
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
- (2018) Rachel Ryu et al. Frontiers in Oncology
- FDG PET/CT for assessing tumour response to immunotherapy
- (2018) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
- (2018) Matthew J. Bott et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
- (2017) Aadel A. Chaudhuri et al. Cancer Discovery
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
- (2017) Natasha K. Brockwell et al. Cancer Immunology Research
- Immune Checkpoint Inhibitors: Basics and Challenges
- (2017) Bin Li et al. CURRENT MEDICINAL CHEMISTRY
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer
- (2015) Chi-Fu Jeffrey Yang et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- (2015) Gideon M. Blumenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
- (2014) S. V. Hato et al. CLINICAL CANCER RESEARCH
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
- Positron Emission Tomography in Staging Early Lung Cancer
- (2013) Donna E. Maziak ANNALS OF INTERNAL MEDICINE
- Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy
- (2013) William N. William et al. Journal of Thoracic Oncology
- Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
- (2012) Apar Pataer et al. Journal of Thoracic Oncology
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
- (2010) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival
- (2009) Katherine R. Birchard et al. CANCER
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started